Bill Gates to spend $912 million to fight AIDS, tuberculosis, malaria
Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
HQ Team July 10, 2025: Gilead Sciences Inc. and the Global Fund have signed a pact to supply an HIV prevention drug at.
All the US Agency for International Development (USAID) direct hire personnel have been placed on administrative leave globally.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow.
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.
HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.
HIV vaccine trials conducted in Eastern and Southern Africa threw up surprising results when more infections were reported in the two vaccine groups.
A person dies every minute due to AIDS-related causes, and the world is off-track to achieve its goals with a quarter of 39.9.
HQ Team March 31, 2024: US-based Varda Space Industries’ spacecraft in orbit crystallised a metastable form of a drug for HIV/AIDS — furthering.
HQ Team July 24, 2023: British pharmaceutical firm, GSK Plc., has got marketing authorization from the European Medicines Authority for its injectable, and.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com